What is the recommended dosing for St. John's wort (Hypericum perforatum) in treating mild to moderate depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

St. John's Wort Dosing for Depression

Start with 300 mg of standardized extract (0.3% hypericin) three times daily for a total of 900 mg/day, and if response is inadequate after 4 weeks, increase to 1200 mg/day (400 mg three times daily). 1

Standard Dosing Protocol

  • Initial dose: 300 mg of standardized extract (0.3% hypericin) three times daily, totaling 900 mg/day 1
  • Duration before dose adjustment: Continue initial dose for at least 4 weeks to assess response 1
  • Dose escalation: If inadequate response after 4 weeks, increase to 1200 mg/day (400 mg three times daily) 1
  • Acute treatment phase: Minimum 6-12 weeks required to establish efficacy 1

The American College of Physicians provides this specific dosing framework based on the standardized extracts used in clinical trials demonstrating efficacy comparable to second-generation antidepressants 1. This dosing applies specifically to mild-to-moderate depression, where St. John's wort shows similar response rates (54% vs. 52%) and remission rates (36% vs. 30%) compared to SSRIs 1.

Critical Safety Considerations Before Prescribing

Absolute contraindications:

  • Concurrent use with monoamine oxidase inhibitors (MAOIs) or serotonin reuptake inhibitors (SSRIs) due to serotonin syndrome risk 2, 3
  • Patients taking oral contraceptives (reduces effectiveness, risking unintended pregnancy) 2, 3
  • Patients on immunosuppressants like cyclosporine or tacrolimus (may cause transplant rejection) 2, 3

Relative contraindications requiring careful consideration:

  • Warfarin therapy (reduces anticoagulant effectiveness) 2
  • Cancer chemotherapy, particularly dasatinib or imatinib (unpredictably decreases plasma concentrations) 2
  • HIV medications (significantly decreases protease inhibitor levels) 2
  • Anticonvulsants (may reduce carbamazepine, phenytoin, phenobarbital levels) 2

St. John's wort is a potent inducer of cytochrome P450 3A4 and P-glycoprotein, causing clinically significant drug interactions 2, 3. The American College of Physicians emphasizes that St. John's wort is not FDA-regulated in the United States, with no standardization of content or potency 1, 3.

Efficacy and Tolerability Profile

  • Better tolerability than SSRIs: Discontinuation rates due to adverse events are significantly lower (4% vs. 7%) 1
  • Overall discontinuation rates: 12% for St. John's wort vs. 16% for antidepressants 1
  • Comparable efficacy: Moderate-quality evidence confirms similar effectiveness to second-generation antidepressants 4, 1

Special Population Considerations

  • Older adults (60-80 years): Equal effectiveness and similar adverse event rates compared to SSRIs, though evidence quality is low 1, 2
  • Severe depression or high suicidality: St. John's wort is not appropriate; cognitive behavioral therapy or standard antidepressants are strongly recommended 3, 5

Clinical Decision Algorithm

St. John's wort is appropriate when ALL of the following criteria are met:

  1. Diagnosis of mild-to-moderate depression (not severe) 1, 5
  2. No concurrent medications with CYP3A4 interactions 2, 3
  3. Not taking oral contraceptives, immunosuppressants, or anticoagulants 2
  4. Patient cannot tolerate standard antidepressants OR prefers herbal treatment 1
  5. Access to quality-controlled European preparations (if possible, given lack of U.S. standardization) 1

If any criterion is not met: Choose cognitive behavioral therapy or second-generation antidepressants as first-line treatment per American College of Physicians strong recommendation 2, 3.

Common Pitfalls to Avoid

  • Assuming all St. John's wort preparations are equivalent: Lack of FDA regulation means significant variability in U.S. products 1, 3
  • Failing to screen for drug interactions: Always obtain complete medication list including over-the-counter drugs before prescribing 2
  • Inadequate treatment duration: Must continue for minimum 6-12 weeks before declaring treatment failure 1
  • Transitioning directly from SSRIs: Allow 24-48 hours washout period to avoid serotonin syndrome 2

References

Guideline

St. John's Wort for Mild-to-Moderate Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

St. John's Wort for Depression and Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

St. John's Wort for Depression Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.